International COVID-19 Blood Cancer Coalition (ICBCC)

March 9, 2022

A multi-stakeholder coalition consisting of representatives from the global patient advocacy and clinical community has formed the International COVID-19 Blood Cancer Coalition (ICBCC) to address the specific impact of the pandemic on immunocompromised blood cancer patients (both acute and chronic), like those living with acute leukemia and to recommend solutions and actions to mitigate those risks. 

Our colleagues from CLL Advocates Network (CLLAN) are leading the secretariat on behalf of the coalition.

The coalition has prepared a Joint Patient Impact Statement for use in different countries to aid when advocating for the provision of anti-COVID-19 treatment and care for immunocompromised or immunosuppressed (IC/IS) blood cancer patients.

The Statement has by now been endorsed by > 50 networks and national organisations of the global patient advocacy community as well as 16 renowned medical societies and representatives from the global clinical community.

List of endorsers: Endorsers

For more information on the coalition, visit ICBCC website :